Travaux scientifiques

Prof. Dr. Özge Gümüşay

69 publications. La source de l’information est indiquée à côté de chaque publication.

Retour au profil

  1. Beyond CDK4/6 Inhibition: Current Strategies in Hormone Receptor-Positive Metastatic Breast Cancer

    Current Treatment Options in Oncology, 2026

    DOI 10.1007/s11864-026-01391-3 PMID 41999452 2 citations (Europe PMC) Texte intégral en libre accèsSource : OpenAlex

  2. Immune-related adverse events as predictors of pathological complete response in early-stage triple-negative breast cancer treated with pembrolizumab

    Immunotherapy, 2026

    DOI 10.1080/1750743x.2026.2662201 PMID 42011533 4 citations (Europe PMC) Texte intégral en libre accèsSource : OpenAlex

  3. Real-World Treatment Efficacy of Ribociclib or Palbociclib Plus Fulvestrant in Hormone Receptor-Positive/HER2-Negative Metastatic Breast Cancer: Turkish Oncology Group (TOG) Study

    Clinical Breast Cancer, 2025

    DOI 10.1016/j.clbc.2025.03.003 PMID 40190010 2 citations (Europe PMC) Texte intégral en libre accèsSource : OpenAlex

  4. HER2-low expression in patients with hormone receptor positive and HER2 negative advanced breast cancer treated with ribociclib or palbociclib in combination with endocrine therapy

    Turkish Journal of Clinics and Laboratory, 2025

    DOI 10.18663/tjcl.1639022 1 citation (OpenAlex) Texte intégral en libre accèsSource : OpenAlex

  5. Abstract P4-11-03: Prediciting high risk hormone receptor (HR) positive Her-2 negative early breast cancer (BC) by artificial intelligence (AI) algorithms

    Clinical Cancer Research, 2025

    DOI 10.1158/1557-3265.sabcs24-p4-11-03 Source : OpenAlex

  6. Real-world data on the efficacy and safety of trastuzumab emtansine in patients with metastatic breast cancer previously treated with pertuzumab: Turkish oncology group multicenter study

    Journal of Chemotherapy, 2024

    DOI 10.1080/1120009x.2024.2366683 PMID 38904164 1 citation (Europe PMC) Source : OpenAlex

  7. Adrenocortical Cancer in the Real World: A Comprehensive Analysis of Clinical Features and Management from the Turkish Oncology Group (TOG)

    Clinical Genitourinary Cancer, 2024

    DOI 10.1016/j.clgc.2024.102077 PMID 38626660 2 citations (Europe PMC) Source : OpenAlex

  8. Activity of CDK4/6 inhibitors and parameters affecting survival in elderly patients in age-subgroups: Turkish Oncology Group (TOG) retrospective study

    BMC Cancer, 2024

    DOI 10.1186/s12885-024-13357-5 PMID 39736618 4 citations (Europe PMC) Texte intégral en libre accèsSource : OpenAlex

  9. Real-world outcomes of pazopanib in metastatic soft tissue sarcoma: a retrospective Turkish oncology group (TOG) study

    Journal of Cancer Research and Clinical Oncology, 2023

    DOI 10.1007/s00432-023-04766-3 PMID 37067546 7 citations (Europe PMC) Texte intégral en libre accèsSource : OpenAlex

  10. Treatment efficacy of ribociclib or palbociclib plus letrozole in hormone receptor-positive/HER2-negative metastatic breast cancer

    Future Oncology, 2023

    DOI 10.2217/fon-2022-1287 PMID 37133230 22 citations (Europe PMC) Texte intégral en libre accèsSource : OpenAlex

  11. Systemic therapy for hormone receptor‐positive/human epidermal growth factor receptor 2‐negative early stage and metastatic breast cancer

    CA A Cancer Journal for Clinicians, 2023

    DOI 10.3322/caac.21777 PMID 36939293 182 citations (Europe PMC) Source : OpenAlex

  12. A phase Ib/II study of eribulin in combination with cyclophosphamide in patients with advanced breast cancer

    Breast Cancer Research and Treatment, 2023

    DOI 10.1007/s10549-023-07073-0 PMID 37815684 3 citations (Europe PMC) Texte intégral en libre accèsSource : OpenAlex

  13. Advancing Immunotherapy in Gastroesophageal Cancer Through Rational Combinations and Biomarkers

    Immunotherapy, 2023

    DOI 10.2217/imt-2022-0287 PMID 37291863 2 citations (Europe PMC) Source : OpenAlex

  14. PET/CT, an important imaging modality in the management of sarcoma patients

    Medicine Science | International Medical Journal, 2023

    DOI 10.5455/medscience.2023.09.187 Source : OpenAlex

  15. Pazopanib in metastatic soft tissue sarcoma (STS): Results of a multi-institutional observational study.

    Journal of Clinical Oncology, 2022

    DOI 10.1200/jco.2022.40.16_suppl.e23542 2 citations (OpenAlex) Source : OpenAlex

  16. Pazopanib in metastatic soft tissue sarcoma (STS): Results of a multi-institutional observational study.

    Bursa Uludag University - AVESIS, 2022

    Source : OpenAlex

  17. Emerging treatment strategies for metastatic triple-negative breast cancer

    Therapeutic Advances in Medical Oncology, 2022

    DOI 10.1177/17588359221086916 PMID 35422881 39 citations (Europe PMC) Texte intégral en libre accèsSource : OpenAlex

  18. CDK4/6 Inhibitors: Mechanisms of Resistance and Potential Biomarkers of Responsiveness in Breast Cancer

    Future Oncology, 2022

    DOI 10.2217/fon-2021-0842 PMID 35137602 18 citations (Europe PMC) Source : OpenAlex

  19. Immunotherapy in Breast Cancer and the Potential Role of Liquid Biopsy

    Frontiers in Oncology, 2022

    DOI 10.3389/fonc.2022.802579 PMID 35372077 13 citations (Europe PMC) Texte intégral en libre accèsSource : OpenAlex

  20. The role of percutaneous vertebral augmentation in patients with metastatic breast cancer: Literature review including report of two cases

    The Breast, 2022

    DOI 10.1016/j.breast.2022.03.016 PMID 35397256 5 citations (Europe PMC) Texte intégral en libre accèsSource : OpenAlex

  21. Reshaping Treatment Paradigms for Advanced Renal Cell Cancer Patients and Improving Patient Management

    Current Treatment Options in Oncology, 2022

    DOI 10.1007/s11864-022-00966-0 PMID 35316480 3 citations (Europe PMC) Source : OpenAlex

  22. Alpelisib induced interstitial lung disease in a patient with advanced breast cancer

    Journal of Oncology Pharmacy Practice, 2022

    DOI 10.1177/10781552221107532 PMID 35730191 3 citations (Europe PMC) Source : OpenAlex

  23. Clinical outcome and characteristics of Turkish breast cancer patients during SARS-Cov-2 pandemic: Single center experience.

    Journal of Clinical Oncology, 2022

    DOI 10.1200/jco.2022.40.16_suppl.e13049 Source : OpenAlex

  24. Should One Use the Combination of Abiraterone and Poly(ADP-ribose) Polymerase Inhibitors as First-Line Therapy for all Patients with Metastatic Castration-Resistant Prostate Cancer?

    Future Oncology, 2022

    DOI 10.2217/fon-2022-0668 PMID 36651304 Source : OpenAlex

  25. Optimal Treatment for Patients with Oligometastatic Prostate Cancer

    Urologia Internationalis, 2021

    DOI 10.1159/000519386 PMID 34700315 1 citation (Europe PMC) Texte intégral en libre accèsSource : OpenAlex

  26. Trials of Immunotherapy in Triple Negative Breast Cancer

    Current Breast Cancer Reports, 2021

    DOI 10.1007/s12609-021-00418-y Source : OpenAlex

  27. Understanding relevant immune mechanisms in gastrointestinal oncology

    Journal of Oncology Pharmacy Practice, 2021

    DOI 10.1177/1078155221992862 PMID 33557689 Source : OpenAlex

  28. Abstract PS2-19: Circulating tumor cell (CTC) enumeration in a phase II trial of pazopanib in addition to endocrine therapy in patients with hormone resistant advanced breast cancer (ABC)

    Cancer Research, 2021

    DOI 10.1158/1538-7445.sabcs20-ps2-19 Source : OpenAlex

  29. Strategic Combinations to Prevent and Overcome Resistance to Targeted Therapies in Oncology

    American Society of Clinical Oncology Educational Book, 2020

    DOI 10.1200/edbk_280845 PMID 32453634 17 citations (Europe PMC) Source : OpenAlex

  30. The DNA damaging revolution

    Critical Reviews in Oncology/Hematology, 2020

    DOI 10.1016/j.critrevonc.2020.103117 PMID 33059228 11 citations (Europe PMC) Source : OpenAlex

  31. Can you draw the picture of happiness– Treatment of a young woman with breast cancer during the COVID-19 pandemic

    Asian Journal of Psychiatry, 2020

    DOI 10.1016/j.ajp.2020.102174 PMID 32464519 Texte intégral en libre accèsSource : OpenAlex

  32. A phase Ib/II study of eribulin with cyclophosphamide (EC) in patients (pts) with advanced breast cancer (ABC).

    Journal of Clinical Oncology, 2020

    DOI 10.1200/jco.2020.38.15_suppl.e13079 Source : OpenAlex

  33. Pazopanib (PZ) plus endocrine therapy as treatment for hormone resistant advanced breast cancer (ABC).

    Journal of Clinical Oncology, 2020

    DOI 10.1200/jco.2020.38.15_suppl.1068 Source : OpenAlex

  34. Does primary tumor localization has prognostic importance in seminoma patients?: Turkish Oncology Group Study.

    PubMed, 2020

    PMID 32521916 Source : OpenAlex

  35. Ezrin is a prognostic biomarker in patients with clear cell metastatic renal cell carcinoma receiving sunitinib

    Journal of Cancer Research and Therapeutics, 2019

    DOI 10.4103/jcrt.jcrt_372_18 PMID 34121685 2 citations (Europe PMC) Source : OpenAlex

  36. Failure of Concurrent Chemoradiotherapy for Organ Preservation in Laryngeal Cancer: Survival Outcomes and Recurrence Patterns

    Ear Nose & Throat Journal, 2019

    DOI 10.1177/0145561319839788 PMID 30983390 5 citations (Europe PMC) Texte intégral en libre accèsSource : OpenAlex

  37. Türkiye’xxde metastatik meme kanserinde Her2 hedefli tedavide pertuzumab kullanımı erken dönem güvenlilik verileri

    Kocaeli Üniversitesi - AVESİS, 2018

    Source : OpenAlex

  38. Türkiye'de Metastatik Meme Kanserinde HER-2 Hedefli Tedavide Pertuzumab Kullanımının Erken Dönem Güvenlik Verileri

    Van Yüzüncü Yıl University Academic Data Management System, 2018

    Source : OpenAlex

  39. Carbonic anhydrase IX is a prognostic biomarker in glioblastoma multiforme

    Neuropathology, 2018

    DOI 10.1111/neup.12485 PMID 29952031 28 citations (Europe PMC) Source : OpenAlex

  40. Pazopanib-Induced Hepatotoxicity in an Experimental Rat Model

    Chemotherapy, 2018

    DOI 10.1159/000481795 PMID 29393107 5 citations (Europe PMC) Source : OpenAlex

  41. Efficiency and safety of regorafenib in metastatic colorectal cancer (mCRC): Real life experience from Turkey.

    Journal of Clinical Oncology, 2018

    DOI 10.1200/jco.2018.36.15_suppl.e15551 Source : OpenAlex

  42. Merkel cell carcinoma in Turkey: A multicentric study.

    Journal of Clinical Oncology, 2018

    DOI 10.1200/jco.2018.36.15_suppl.e21591 Source : OpenAlex

  43. The assessment of incidental thyroid lesions on 18F-fluorodeoxyglucose positron emission tomography/computed tomogrophy: A single centre experience

    Journal of Oncological Sciences, 2017

    DOI 10.1016/j.jons.2017.03.003 1 citation (OpenAlex) Texte intégral en libre accèsSource : OpenAlex

  44. Advances of Molecular Targeted Therapy in Gastric Cancer

    Journal of Gastrointestinal Cancer, 2016

    DOI 10.1007/s12029-016-9806-8 PMID 26875080 17 citations (Europe PMC) Source : OpenAlex

  45. Crizotinib-induced toxicity in an experimental rat model

    Wiener klinische Wochenschrift, 2016

    DOI 10.1007/s00508-016-0984-y PMID 26975454 3 citations (Europe PMC) Source : OpenAlex

  46. Abdominal wall perforation in a patient with recurrent epithelial ovarian cancer after bevacizumab treatment

    Journal of Oncological Sciences, 2016

    DOI 10.1016/j.jons.2016.07.010 1 citation (OpenAlex) Texte intégral en libre accèsSource : OpenAlex

  47. Tumor homing to the oral cavity after tooth extraction in a patient with metastatic lung adenocancer: A case report

    Journal of Oncological Sciences, 2016

    DOI 10.1016/j.jons.2015.11.002 Source : OpenAlex

  48. The impact of immunohistochemical staining with ezrin-carbonic anhydrase IX and neuropilin-2 on prognosis in patients with metastatic renal cell cancer receiving tyrosine kinase inhibitors

    Tumor Biology, 2015

    DOI 10.1007/s13277-015-3589-6 PMID 26026587 5 citations (Europe PMC) Source : OpenAlex

  49. Small cell neuroendocrine carcinoma of the posterior tongue

    Journal of Cancer Research and Therapeutics, 2015

    DOI 10.4103/0973-1482.140778 PMID 26458628 3 citations (Europe PMC) Source : OpenAlex

  50. Factors Influencing Chemotherapy Goal Perception in Newly Diagnosed Cancer Patients

    Journal of Cancer Education, 2015

    DOI 10.1007/s13187-015-0827-y PMID 25851203 4 citations (Europe PMC) Source : OpenAlex